QurientPipeline


 

Pipeline

Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.

Discovery Candidate Pre-Clinical Phase 1 Phase 2 Phase 3
Anti
Cancer
Axl/Mer/CSF1R
Inhibitor
(Q702)
Immuno
Oncology
Drug Resistant
NSCLC
Selective
CDK7
Inhibitor
Solid
Tumor
Antibiotics Cyt bc1 Inhibitor
(Telacebec,
Q203)
Drug Resistant
Tuberculosis
Anti
Inflammation
Topical 5LO
Inhibitor
(Q301)
Atopic
Dermatitis
Oral
5LO Inhibitor
Asthma
Candidate Pre-Clinical Phase 1 Phase 2
Axl/Mer/
CSF1R
Inhibitor
(Q702)
Immuno
Oncology
Drug
Resistant
NSCLC
Selective
CDK7
Inhibitor
Solid
Tumor
Cytbc1
Inhibitor
(Telacebec,
Q203)
Drug
Resistant
Tuberculosis
Topical
5LO Inhibitor
(Q301)
Atopic
Dermatitis
Oral
5LO
Inhibitor
Asthma
information for download file